Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial
This Phase 1 trial indicated that COVAC-2 is safe and induces high levels of both antigen-specific binding and neutralizing antibodies by Day 42-56 with levels beginning to wane by Day 120.
Authors
- Rachelle Buchanan
- Erin Scruten (ORCID: https://orcid.org/0000-0001-5307-5717)
- Trina Racine (ORCID: https://orcid.org/0000-0001-6370-8661)
- Thomas Courant (ORCID: https://orcid.org/0000-0002-1566-4382)
- Luc Gagnon
- Supriya Arora (ORCID: https://orcid.org/0000-0002-1992-0822)
- Glenn Hamonic (ORCID: https://orcid.org/0000-0001-5188-131X)
- Élodie Pastural
- Matthieu Daugan
- Darryl Falzarano (ORCID: https://orcid.org/0000-0002-8805-8068)
- Scott A. Halperin (ORCID: https://orcid.org/0000-0003-0525-589X)
- Nicolas Collin (ORCID: https://orcid.org/0000-0002-9304-3813)
- Lingyun Ye (ORCID: https://orcid.org/0000-0002-3260-5157)
- Volker Gerdts (ORCID: https://orcid.org/0000-0001-8229-1611)
- J. Lew (ORCID: https://orcid.org/0009-0002-1685-3596)
- May ElSherif (ORCID: https://orcid.org/0000-0002-0268-7841)
- Stephen Sanche (ORCID: https://orcid.org/0000-0003-3643-5973)
- Roland Ventura
- Sylvia van Drunen Little-van den Hurk
- Joanne M. Langley (ORCID: https://orcid.org/0000-0003-3270-7345)
- Yun Cai
- Paul E. Hodgson
Institutions
- University of Saskatchewan (CA)
Publication Details
- Journal
- Vaccine
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1016/j.vaccine.2025.127748
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Innovation Saskatchewan
- Coalition for Epidemic Preparedness Innovations
- Western Economic Diversification Canada